ADVERUM BIOTECHNOLOGIES INC's ticker is ADVM and the CUSIP is 00773U108. A total of 80 filers reported holding ADVERUM BIOTECHNOLOGIES INC in Q3 2022. The put-call ratio across all filers is 0.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $29,826 | -39.0% | 19,884 | -35.4% | 0.00% | – |
| Q2 2023 | $48,905 | +116.4% | 30,758 | -2.4% | 0.00% | – |
| Q1 2023 | $22,602 | +61.4% | 31,506 | +119.1% | 0.00% | – |
| Q3 2022 | $14,000 | -33.3% | 14,377 | -16.9% | 0.00% | – |
| Q2 2022 | $21,000 | +10.5% | 17,306 | +17.7% | 0.00% | – |
| Q1 2022 | $19,000 | -83.6% | 14,702 | -77.8% | 0.00% | -100.0% |
| Q4 2021 | $116,000 | -14.1% | 66,118 | +6.5% | 0.00% | -50.0% |
| Q3 2021 | $135,000 | -53.4% | 62,089 | -25.2% | 0.00% | -33.3% |
| Q2 2021 | $290,000 | +15.5% | 82,959 | +226.4% | 0.00% | 0.0% |
| Q1 2021 | $251,000 | -82.2% | 25,420 | -81.4% | 0.00% | -85.7% |
| Q3 2020 | $1,411,000 | +365.7% | 136,966 | +341.8% | 0.02% | +162.5% |
| Q1 2020 | $303,000 | -31.3% | 31,000 | -19.1% | 0.01% | 0.0% |
| Q4 2019 | $441,000 | +401.1% | 38,310 | +37.6% | 0.01% | +100.0% |
| Q4 2018 | $88,000 | +22.2% | 27,840 | +105.7% | 0.00% | 0.0% |
| Q2 2018 | $72,000 | -72.5% | 13,531 | -70.1% | 0.00% | -73.3% |
| Q1 2018 | $262,000 | – | 45,245 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sonic Fund II, L.P. | 4,112,355 | $40,178,000 | 34.81% |
| Versant Venture Management, LLC | 7,068,233 | $69,056,636,000 | 18.94% |
| ACUTA CAPITAL PARTNERS, LLC | 1,704,500 | $16,653,000 | 8.07% |
| Soleus Capital Management, L.P. | 313,900 | $3,067,000 | 3.57% |
| Ghost Tree Capital, LLC | 1,305,500 | $12,755,000 | 3.38% |
| SAN FRANCISCO SENTRY INVESTMENT GROUP (CA) | 480,000 | $4,690,000 | 2.97% |
| RTW INVESTMENTS, LP | 6,631,627 | $64,791,000 | 2.79% |
| VR Adviser, LLC | 994,381 | $9,715,000 | 2.63% |
| Avoro Capital Advisors LLC | 7,150,000 | $69,856,000 | 2.36% |
| RA Capital Management | 7,272,714 | $71,054,000 | 2.24% |